This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Drug Enforcement Administration wants to increase the amount of cannabis and psychedelics it researches in 2023. The post DEA wants to boost production of cannabis and psychedelics research in 2023? appeared first on Leafly.
The Department of Health and Human Services (HHS) recommended to the Drug Enforcement Administration (DEA) this week that cannabis be moved from Schedule I to Schedule III. The DEA need not follow HHS’s recommendation, so this is in no way a done deal.
Senator Raphael Warnock (D-GA) DEA ACT Another cannabis act was introduced late last week, the Deferring Executive Authority Act (DEA). And I would support all of the provisions and reforms in this legislation if paired with broader cannabis reforms that substantively addressed the issue of restorative justice.
On May 4, 2023, during its annual Supply Chain Conference, the Drug Enforcement Administration (DEA) announced that it is “in the process of modifying [its regulations]” on cannabis constituents based on recommendations from the U.S. Department of Health and Human Services (HHS).
Marijuana Moment reports The Drug Enforcement Administration (DEA) will soon be proposing new rules to clarify that synthetically manufactured cannabinoids like delta-8 THC are prohibited controlled substances.
Here is what they say The DEA Report on Ayahuasca Risks: “Science” in Service of Prohibition? On February 2023, the Drug Enforcement Administration (DEA) released a document to the legal team representing the Church of the Eagle and the Condor (CEC).
The US Drug Enforcement Administration (DEA) issued a letter on June 9, 2023 in response to a request about information regarding, among other things, tetrahydrocannabinolic acid (THCa). A copy of the letter is below. Note that I was only able to locate a copy of the letter on Reddit. I had to compile a series […]
For some perspective on the matter, Project CBD turned to Marc Scialdone, a molecular chemist with Saint Michaels College in Vermont, who co-authored a 2023 paper for the International Cannabinoid Research Society ( ICRS ) entitled The Dark Side of Cannabidiol. “The market crashed.
We thought the market would expand “quite a bit” in 2023 – well, the “a bit” part was right. And not to ruin the ending, but no retail market will open in 2023. As of now, this is still a proposal, and it’s anyone’s guess if the DEA (who would do the actual re-scheduling) will think that’s a good idea. by a large margin.
The DEA sends a letter to Georgia pharmacies. Well, apparently the Drug Enforcement Administration (DEA) noted that as well, and they didn’t take kindly to it. But wait, isn’t there a provision that prohibits the Department of Justice (of which DEA is a part) from interfering with state legal medical marijuana programs?
February 13, 2023 Business and Commerce Law, Distributors, I have been concerned about the proliferation of THC acetate ester (THCO) for a while. It has always been my view that THCO is a controlled substance under federal law. Although it can be made from cannabinoids from hemp, THCO is not naturally expressed by the hemp plant.
LaBruyere on March 9, 2023 Last week, we wrote about the Drug Enforcement Administration’s (DEA) February 13, 2023 response letter stating that delta-8 THCO and delta-9 THCO – two forms of THC acetate ester (THCO) – are illegal controlled substances under federal law. The DEA’s decision centered on THCO’s “synthetic” nature.
Marijuana Moment report on some of the panels being proposed for 2023…… Voting is now open for the public to decide which panels will make the stage at next year’s South By Southwest (SXSW) festival—and there are about 100 marijuana- and psychedelics-related proposals to pick from. Which Political Party Will Legalize Weed?
February 21 2023 On February 13, I posted an article about the DEA’s response to my inquiry regarding the legal status of THCO. As my readers are aware, the DEA stated that THCO is a schedule 1 controlled substance. The DEA’s position, which was spread via my article, created what several people have called a “shitstorm”.
Bright Green will be operating under a Memorandum of Agreement with the Drug Enforcement Administration (DEA). Construction on the facility is scheduled to be completed in 2023. According to a press release by the company, they intend for the facility to be part of a larger national market for cannabis research and products.
Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy. Litigation to compel DEA to respect RTT laws and allow access to psilocybin for therapeutic use is pending before the Ninth Circuit Court of Appeals.
Department of Health and Human Services (HHS) recommended that the Drug Enforcement Agency (DEA) reshedule cannabis as a Schedule III substance in August of 2023. The recommendation for rescheduling cannabis marked the first time a government agency officially recognized cannabis’ medical benefits.
In light of this, the Drug Enforcement Administration (DEA) has announced its intention to substantially increase the production quota of psychedelics such as LSD, psilocybin, and mescaline due to be studied in 2023. . It’s excellent news, particularly since new research suggests psilocybin deserves further investigation.
Testimonies by Wang and Quarles urged committee members to incorporate language into the 2023 Farm Bill that would regulate CBD and other hemp-derived compounds. Wang encouraged committee members to incorporate language into the 2023 Farm Bill found in H.R. The panel’s leaders agreed; Ranking Member Rep. Watch the exchange here.
Doblin and his fellow researchers initially began exploring the therapeutic potential of MDMA back in the early 1980s, but these studies ground to a halt when the DEA banned ecstasy in 1985. If all goes well, the FDA could legalize MDMA-assisted therapy next year, which would make it legally available starting in 2023.
Stay tuned… Oregon plans to accept applications for Facilitators, Laboratories, Manufacturers and Service Centers starting January 2023. The Drug Enforcement Agency (DEA) currently has guidance published for those interested in petitioning for a religious exemption to the CSA. Non-Commercial Operations. Underground Therapists.
In fact, the United States Drug Enforcement Agency (DEA) issued a private letter ruling in September 2021 making clear that so long as Delta-8 has been extracted from a hemp plant (rather than a marijuana plant that contains.3% ” Under this timeline, New Yorkers can expect to see retail sales in approximately April of 2023.
In a much anticipated announcement, the Drug Enforcement Administration (DEA) issued a notice of proposed rulemaking to reschedule marijuana, from Controlled Substances Act (CSA) schedule I to schedule III (the “Proposed Rule”). First , DEA is not proposing an interim final rule. 29, 2023) (“August 2023 Letter”).
The Drug Enforcement Administration (DEA) seems happy to respond to public and private parties inquiring about the control status of various substances. DEA answers some of these inquiries more quickly than others, and the response letters are usually short and to the point. What are the legal ramifications of DEA writing these things?”
The Drug Enforcement Administration (DEA) seems happy to respond to public and private parties inquiring about the control status of various substances. DEA answers some of these inquiries more quickly than others, and the response letters are usually short and to the point. What are the legal ramifications of DEA writing these things?”
In my June 2023 post, I concluded that even if there are good arguments for THCA’s legality, practically speaking law enforcement was likely to consider THCA in calculating total THC, given the fact that THCA converts to THC upon application of heat. But, it bears mentioning that DEA’s interpretations are just that.
Griffen’s article is just one of many parsing the language of the 2018 Farm Bill and a 2023DEA letter on the topic. See also: “ THCA and the DEA: Rod Breaks Down the Latest News ” from Rod Kight, an another attorney prominent in the space. I would say: “Someone over at DEA wrote a letter last year indicating that it’s not.
Revisit provisions of the Farm Bill or interpretations of the Farm Bill pushed by the DEA, which currently make hemp processors susceptible to civil penalties and felony charges for possession or transport of “hot hemp”, regardless of whether the THC limit is 0.3%, or 1.0%. But while you’re processing that hemp you may be committing felonies!,
Earlier this year, we wrote about how MAPS was progressing through the Phase III study process and was targeting FDA approval in 2022 and commercialization in 2023 — if these targets are met, they would be on par with Oregon’s legal psilocybin licensing program.
In a post on August 3, 2023, hemp lawyer Rod Kight analyzed new cannabinoid H4 CBD – one I’d never stumbled into before. And it is not on the CSA (the DEA tried and then backed off efforts to schedule it in 2016). Take this FDA press release from April 2023 for example: On Wednesday the U.S.
Schedule III substances are subject to certain controls not applicable to all other prescription drugs, including the requirement that a medical professional with a specific license issued by the Drug Enforcement Agency (DEA) must conduct an in-person examination before prescribing it.
Suffice it to say that DEA has opined that it is — at least for now. The 2018 Farm Bill is set to expire September 30, 2023. Oregon’s legislative session ends June 25, 2023. So, seeds possessed by OLCC licensees that will germinate into high THC plants would be shippable too. Will SB 353 pass?
REGISTER HERE If you haven’t already registered, please join us on July 25, 2023 at 10am PST for a free webinar on U.S. Drug Enforcement Administration (DEA), Customs and Border Protection (CBP) and their personnel. Import and Export of Marijuana, Hemp, and Paraphernalia. cannabis business lawyer Vince Sliwoski.
Drug Enforcement Agency (DEA) reported that the federalization of hemp would result in hemp shielding criminal activities. Counties may also extend moratoriums, provided they submit an annual request with the ODA by January 1, 2023. In 2020, the U.S. These two counties have imposed local hemp moratoriums in accordance with SB 1564.
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. 9] Experts predict that this therapy could receive full FDA approval as soon as 2023. [10] DEA and the Controlled Substances Act. Under the Controlled Substances Act of 1970, DEA classifies drugs into one of five schedules.
On July 5, 2023, the FDA and FTC jointly announced six cease and desist letters to alleged delta-8 product makers. But, there’s a huge controversy about whether it can be controlled, with agencies like the DEA saying it is. You can access the letters here. You can read more about that issue here or here.
If Congress would like to change the legal status of marijuana, they would do so before or after the DEA makes a final scheduling decision. On May 21, 2024, the DEA opened a 62-day public comment period, which concluded on July 22, 2024. Currently, rescheduling marijuana to Schedule III of the CSA is being considered. What is 280E.
29, 2023, the HHS formally communicated its suggestion to the Drug Enforcement Administration (DEA) to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). The HHS Recommendation In a letter dated Aug.
Study and development of these treatments remain challenging as psilocybin, MDMA, DMT and LSD are all listed as DEA Schedule I drugs. It is anticipated that MDMA will receive FDA approval for PTSD by the end of 2023, and that psilocybin approval will follow. However, change appears imminent.
MDMA is a promising psychedelic compound, currently placed by the Drug Enforcement Administration (DEA) in Schedule I of the Controlled Substances Act, that has been produced for legal research in small batches by certified laboratories. Berra Yazar-Klosinski, Ph.D. contributing author and MAPS PBC Chief Scientific Officer.
REGISTER HERE Please join us on July 25, 2023 at 10am PST for a free webinar on U.S. Drug Enforcement Administration (DEA), Customs and Border Protection (CBP) and their personnel. Import and Export of Marijuana, Hemp and Paraphernalia. cannabis business lawyer Vince Sliwoski.
It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. The company, which began trading on the OTC and Frankfurt Stock exchanges in October, has plans to open as many as 120 more clinics by 2023. Also in November, it reported positive data on its standout IND, CYB003.
“We’re continuing to drive cost savings and operational efficiencies across the company, and remain broadly on track to our target of $150 – $200 million in fiscal 2022- fiscal 2023,” added Mike Lee , CFO. “We Drug Enforcement Administration (the “DEA”), the U.S. First Quarter Fiscal 2022 Financial Summary. hemp industry in the U.S.,
Implementation of supply chain optimization well underway with network optimization and complexity reduction initiatives expected to realize our previously stated cost savings of $150 million to $200 million by the end of the first half of FY 2023. Drug Enforcement Administration (the “DEA”), the U.S.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content